CoChat

Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists

Open access
Reed, Josh, Kanamarlapudi, Venkateswarlu, Bain, Stephen · 2018 · Cardiovascular Endocrinology & Metabolism

The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.

Abstract

Glucagon-like peptide 1 (GLP-1)-based therapies reduce hyperglycaemia in type 2 diabetes. Diabetes cardiovascular comorbidity remains prevalent, although current treatments are effective at reducing hyperglycaemia. GLP-1 exerts specific actions on the cardiovascular system in both healthy individuals and patients with cardiovascular pathology, and GLP-1 therapies have improved the cardiovascular profile of diabetic patients. GLP-1 exerts its action by binding to its receptor (GLP-1 receptor) at the cell surface. Mechanistically, it is not clear how GLP-1 therapies exert beneficial effects on the cardiovascular system. It is difficult to arrive at any conclusions on the ability of GLP-1 receptor agonism to reduce cardiovascular disease from animal/human studies because of varying experimental designs. This review highlights recent findings from long-term human GLP-1 therapy studies, and summarizes postulated mechanisms as to how GLP-1 receptor agonism may alleviate cardiovascular disease.

Overview

Integrity signals

Registry

Crossref · 10.1097/xce.0000000000000147

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 47 references

Cited by

See all 18

Metadata

Authors
Reed, J., Kanamarlapudi, V., & Bain, S.
Affiliations
Swansea University (GB)
Corresponding author
Bain, Stephen
Venue
Cardiovascular Endocrinology & Metabolism
Published
2018-03
Volume
7
Issue
1
Pages
18-23
ISSN
2574-0954 (ISSN-L)
OpenAlex
W2778699832
Cited by
16
References
48
Citations by year
2026: 4 · 2025: 1 · 2024: 5 · 2023: 2 · 2021: 2 · 2020: 2
FWCI
0.08
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Cardiovascular Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
Biotechnology and Biological Sciences Research Council (1095087)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
glucagon-like peptide-1, GLP-1 receptor agonists, cardiovascular disease, type 2 diabetes, hyperglycemia, GLP-1 receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists. https://app.cochat.ai/papers/10.1097/xce.0000000000000147
The paper
Reed, J., Kanamarlapudi, V., & Bain, S. (2018). Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists. Cardiovascular Endocrinology & Metabolism. https://doi.org/10.1097/xce.0000000000000147

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.